Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Globulins, specifically Varicella Zoster Immune Globulin (VZIG), are scientifically validated for use in preventing or modifying the course of chickenpox (varicella) in certain high-risk groups. VZIG is a preparation of human immunoglobulins rich in antibodies against the varicella zoster virus. It is not intended for the routine treatment of established chickenpox in healthy individuals, but is recommended for post-exposure prophylaxis, particularly for immunocompromised patients, pregnant women without immunity, and newborns whose mothers develop chickenpox around the time of delivery. Clinical guidelines from organizations such as the CDC and the American Academy of Pediatrics support its use in these contexts, based on evidence that VZIG can reduce the severity of varicella or prevent it altogether when administered within 10 days of exposure. Several studies have demonstrated that timely administration of VZIG results in fewer complications and milder disease in susceptible individuals. It is not used for routine therapy in uncomplicated chickenpox, as antiviral drugs (e.g., acyclovir) are preferred for treatment. Thus, the use of globulins for chickenpox is well supported by scientific evidence but is reserved for high-risk populations and specific clinical scenarios.

More about Globulins
More about Chicken Pox

Other ingredients used for Chicken Pox

Other health conditions supported by Globulins

Products containing Globulins